文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

不同升压药策略治疗围插管期低血压患者心血管不稳定的发生率

The incidence of cardiovascular instability in patients receiving various vasopressor strategies for peri-intubation hypotension.
PubMed 文献 · Am J Emerg Med · 2022-12-21
一句话结论回顾性队列显示,围插管期低血压患者使用去甲肾上腺素持续输注、去苯肾上腺素推注或两者序贯,2小时内低血压、心动过缓或心脏骤停复合终点无统计学差异。

本研究为回顾性队列研究,纳入3家学术医学中心及较小卫生系统站点急诊科插管后30分钟内因低血压接受升压药的患者,按可能影响升压药选择的因素匹配,分为单用去苯肾上腺素推注(PDPE)、单用去甲肾上腺素(NE)持续输注、PDPE后接NE持续输注三组。主要终点为升压药启动后2小时内低血压(收缩压<90 mmHg)、心动过缓(心率<60次/分)和心脏骤停的复合发生率,三组分别为88.6%、80.0%和88.6%,无统计学差异。脓毒症或脓毒性休克亚组中PDPE使用比例较高(41.3% vs. 27.1%,p=0.075),主要复合终点更常见(p=0.045),但与升压药策略无关(p=0.55)。作者认为升压药选择应继续考虑患者个体因素和产品可及性。

要点

  • 纳入插管后30分钟内因低血压启动升压药的患者,升压药启动平均时间为插管后10分钟。
  • 主要复合终点(2小时内收缩压<90 mmHg、心率<60次/分或心脏骤停)三组分别为NE组88.6%、PDPE组80.0%、PDPE+NE组88.6%,无统计学差异。
  • 脓毒症或脓毒性休克亚组更常先使用PDPE再启动NE持续输注(41.3% vs. 27.1%,p=0.075),主要复合终点更常见(p=0.045),但与升压药策略无关(p=0.55)。
  • 作者认为围插管期低血压启动升压药后的心血管不稳定不因所选升压药策略而异,脓毒症或脓毒性休克患者亦然。
  • 作者认为升压药选择应继续包括患者个体因素和产品可及性。

适用人群与场景

  • 3家学术医学中心及较小卫生系统站点的急诊科患者,插管后30分钟内因低血压接受升压药。

处置流程与药物剂量

  • 围插管期低血压升压药策略包括:去甲肾上腺素(NE)持续输注、去苯肾上腺素推注(PDPE)、或PDPE后接NE持续输注,目标为达到目标平均动脉压。

研究设计与关键结果

  • 回顾性队列研究,筛查2518例患者,匹配后纳入105例。
  • 升压药启动平均时间为插管后10分钟。
  • 主要复合终点(升压药启动后2小时内低血压[收缩压<90 mmHg]、心动过缓[心率<60次/分]和心脏骤停)发生率:NE组88.6%、PDPE组80.0%、PDPE+NE组88.6%,组间无统计学差异。
  • 脓毒症或脓毒性休克亚组更常先使用PDPE再启动NE持续输注(41.3% vs. 27.1%,p=0.075),主要复合终点更常见(p=0.045),但与升压药策略无关(p=0.55)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,围插管期低血压启动升压药后的心血管不稳定不因所选升压药策略(NE持续输注、PDPE或PDPE后接NE持续输注)而异,脓毒症或脓毒性休克患者亦然。
  • 作者认为,升压药选择应继续包括患者个体因素和产品可及性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Patients frequently experience hypotension in the peri-intubation period. This can be due to the underlying disease process, physiologic response to the intervention, or adverse effect from medications. With the heterogeneity in cause for hypotension, the duration can also be short or prolonged. Initiation of vasopressors for peri-intubation hypotension includes various strategies using continuous infusion norepinephrine (NE) or push-dose phenylephrine (PDPE) to obtain goal mean arterial pressure. There is a paucity of data describing cardiovascular stability outcomes in patients receiving vasopressors for peri-intubation hypotension.

METHODS: This is a retrospective cohort study including emergency department patients across three academic medical centers and smaller health system sites who received vasopressors for hypotension within 30 min of intubation. Patients were matched based on factors likely to influence vasopressor selection and were divided into groups if they received PDPE alone, continuous infusion NE alone, or PDPE followed by continuous infusion NE. The primary outcome was a composite of the incidence of hypotension (systolic blood pressure < 90 mmHg), bradycardia (HR < 60 beats per minute), and cardiac arrest within 2 h following initiation of vasopressors.

RESULTS: Screening occurred for 2518 patients, with 105 patients undergoing matching. Mean time to vasopressor initiation was 10 min following intubation. The composite primary outcome was not statistically different between groups and occurred 88.6%, 80.0%, and 88.6% in the NE, PDPE, and PDPE+NE groups, respectively. A subgroup analysis of patients with an ED diagnosis of sepsis or septic shock were more likely to receive PDPE before starting continuous infusion NE (41.3% vs. 27.1%, p = 0.075) and more frequently experienced the primary composite outcome (p = 0.045) but was not correlated with vasopressor strategy (p = 0.55).

DISCUSSION: Cardiovascular instability following vasopressor initiation for peri-intubation hypotension was no different depending on the selected vasopressor strategy. This held true in patients with a sepsis or septic shock diagnosis. Selection of vasopressors should continue to include patient specific factors and product availability.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Schmitt CJ, Mattson AE, Brown CS, et al. The incidence of cardiovascular instability in patients receiving various vasopressor strategies for peri-intubation hypotension. Am J Emerg Med. 2022. PMID: 36603354. doi:10.1016/j.ajem.2022.12.020

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。